HC Wainwright & Co. Initiates Coverage On Upstream Bio with Buy Rating, Announces Price Target of $36
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Upstream Bio (NASDAQ:UPB) with a Buy rating and announces Price Target of $36.
HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Upstream Bio (NASDAQ:UPB) with a Buy rating and announces Price Target of $36.